Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 21

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 2
Chunk 21
---
ortization of acquired intangible assets$14,322 $14,322 —%$28,644 $28,644 —%

As part of the Flexion Acquisition and the MyoScience Acquisition, we acquired intangible assets consisting of developed technology intangible assets and customer relationships, with estimated useful lives between 9 and 14 years. For more information, see Note 8, Goodwill and Intangible Assets, to our condensed consolidated financial statements included herein.

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 49

Contingent Consideration (Gains) Charges, Acquisition-related Expenses, Restructuring and Other

The following table provides a summary of the costs related to the contingent consideration (gains) charges, acquisition-related expenses, restructuring and other during the periods indicated, including percent changes (dollar amounts in thousands): 

Three Months EndedJune 30,% Increase / (Decrease)Six Months EndedJune 30,% Increase / (Decrease)2025202420252024Contingent consideration (gains) charges$(357)$1,509 N/A$(3,032)$(2,297)32%Restructuring charges— 996 (100)%— 6,531 (100)%Acquisition-related expenses991 230 100+%2,502 404 100+%Legal settlement— — N/A7,000 — N/ATotal contingent consideration (gains) charges, acquisition-related expenses, restructuring and other$634 $2,735 (77)%$6,470 $4,638 39%

Total contingent consideration (gains) charges, acquisition-related expenses, restructuring and other included net charges that decreased 77% in the three months ended June 30, 2025 versus 2024. Total contingent consideration (gains) charges, acquisition-related expenses, restructuring and other included net charges that increased 39% in the six months ended June 30, 2025 versus 2024.

During the three and six months ended June 30, 2025, we recognized contingent consideration gains of $0.4 million and $3.0 million, respectively, primarily due to revisions to the latest discount rates.

During the three months ended June 30, 2024, we recognized a contingent consideration charge of $1.5 million primarily due to revisions to the latest discount rates. During the six months